John Martin is the former CEO and executive chairman of Gilead Sciences, a pharmaceutical company.
Martin joined Gilead in 1990 as the vice president of research and development before assuming the CEO role in 1996, a position he would hold for 20 years.
He transitioned from his role as president and CEO to chairman and CEO in 2008. After eight years, he became Gilead’s executive chairman in 2016.
While running the pharmaceutical company, Martin expanded its drug portfolio to 24 marketed products and led the Gilead Access Program—an effort to distribute HIV/AIDS, viral hepatitis, and visceral leishmaniasis medicines.
Before joining Gilead, Martin was the director of antiviral chemistry at Bristol-Myers Squibb beginning in 1984.
Martin currently sits on the boards of Sarepta Therapeutics, Kronos Bio, and The Scripps Research Institute. He has previously served on the boards of the International Society for Antiviral Research as president, BayBio as chair, the California Healthcare Institute as chair, and the Biotechnology Industry Organization.
He has also served on the National Institute of Allergy & Infectious Diseases Council, the External Scientific Advisory Board of the University of California School of Global Health, and the board of trustees of both the University of Chicago and Golden Gate University.
The former CEO offered his expertise on the Presidential Advisory Council on HIV/AIDS and the Centers for Disease Control/Health Resources and Services Administration’s Advisory Committee on HIV and STD Prevention and Treatment.
Martin has received numerous awards and accolades, including the American Chemical Society’s Isbell Award, the Gertrude B. Elion Award for Scientific Excellence from the International Society for Antiviral Research, and the National Academy of Sciences Award for Chemistry in Service to Society. He was also inducted into the National Academy of Engineering in 2008.
Martin earned his bachelor’s degree in chemical engineering at Purdue University, his M.B.A. from Golden Gate University, and his Ph.D. in organic chemistry from the University of Chicago.
What is John C. Martin's net worth?
The estimated net worth of John C. Martin is at least $264.15 million as of December 3rd, 2018. Dr. Martin owns 2,877,762 shares of Gilead Sciences stock worth more than $264,149,774 as of November 14th. This net worth evaluation does not reflect any other investments that Dr. Martin may own. Learn More about John C. Martin's net worth.
How do I contact John C. Martin?
Has John C. Martin been buying or selling shares of Gilead Sciences?
John C. Martin has not been actively trading shares of Gilead Sciences during the last ninety days. Most recently, John C. Martin sold 50,000 shares of the business's stock in a transaction on Monday, December 3rd. The shares were sold at an average price of $71.20, for a transaction totalling $3,560,000.00. Following the completion of the sale, the director now directly owns 2,877,762 shares of the company's stock, valued at $204,896,654.40. Learn More on John C. Martin's trading history.
Who are Gilead Sciences' active insiders?
Gilead Sciences' insider roster includes Gregg Alton (EVP), Paul Carter (EVP), John Cogan (Director), Andrew Dickinson (Exec. VP & CFO ), Andrew Dickinson (CFO), John Martin (Director), Johanna Mercier (Insider), James Meyers (EVP), John Milligan (Insider), Daniel O'Day (Chairman & CEO ), Merdad Parsey (Insider), Brett Pletcher (EVP), Javier Rodriguez (Director), Robin Washington (CFO), Richard Whitley (Director), and Diane Wilfong (CAO). Learn More on Gilead Sciences' active insiders.
Are insiders buying or selling shares of Gilead Sciences?
In the last year, insiders at the biopharmaceutical company sold shares 9 times. They sold a total of 81,679 shares worth more than $6,935,730.32. The most recent insider tranaction occured on November, 6th when insider Merdad Parsey sold 25,590 shares worth more than $2,341,485.00. Insiders at Gilead Sciences own 0.2% of the company.
Learn More about insider trades at Gilead Sciences. Information on this page was last updated on 11/6/2024.